Nextera Overview

  • Year Founded
  • 2009

Year Founded

  • Status
  • Private

  • Employees
  • 19

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 3

Nextera General Information

Description

Developer of novel therapeutic drugs designed to be used in disease-specific treatment. The company's drugs offer improved treatment of major disease classes, such as autoimmune diseases, chronic infections, and cancer, enabling doctors to provide increased therapeutic efficacy concomitantly with fewer off-target side effects.

Contact Information

Website
www.nextera.no
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • Oslo Innovation Center
  • Gaustadalléen 21
  • 0349 Oslo
  • Norway
+47 22 00 00 00

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Nextera Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Secondary Transaction - Private 01-Apr-2021 Completed Generating Revenue
6. Grant 01-Feb-2016 00.000 Completed Generating Revenue
5. Early Stage VC 19-Aug-2012 Completed Startup
4. Secondary Transaction - Private 04-Jul-2012 Completed Startup
3. Early Stage VC 01-May-2011 Completed Startup
2. Early Stage VC 06-Dec-2010 Completed Startup
1. Early Stage VC 01-Aug-2009 Completed Startup
To view Nextera’s complete valuation and funding history, request access »

Nextera Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of novel therapeutic drugs designed to be used in disease-specific treatment. The company's drugs offer improv
Drug Discovery
Oslo, Norway
19 As of 2023
00000000000

000000

fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in
0000 000000000
Ann Arbor, MI
00 As of 0000
00000
000000 - 000 00000

000000

nt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exerc
0000000000000
Gaithersburg, MD
00 As of 0000
00000
0000 0000-00-00
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Nextera Competitors (13)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Lycera Venture Capital-Backed Ann Arbor, MI 00 00000 000000 - 000 00000
000000000 Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
0000000 0000000000 Venture Capital-Backed Wayne, PA 000.00 00000000000 000.00
000000 00000000000 Formerly VC-backed Lexington, MA 00 00000 00000000 00000
00000000 Venture Capital-Backed San Diego, CA 000 00000 000000000 00000
You’re viewing 5 of 13 competitors. Get the full list »

Nextera Patents

  • 37

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 4

    Granted

  • 2

    Pending

  • 000

    Expiring in next 12 mo

Nextera Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-202219299-D0 Vector construct Pending 20-Dec-2022
GB-202219294-D0 Antigen binding proteins Pending 20-Dec-2022
GB-202113858-D0 Peptides Inactive 28-Sep-2021 000000000
CA-3080885-A1 Vector construct Pending 03-Nov-2017 000000000
EP-3704244-A1 Vector construct Pending 03-Nov-2017 C12N15/70
To view Nextera’s complete patent history, request access »

Nextera Executive Team (7)

Name Title Board Seat Contact Info
Geir Løset Ph.D Co-Founder, Chief Executive Officer & CSO
Hans Tjeldflaat Chief Financial Officer
Sven Berger Ph.D Vice President of Research & Development
Hans Ivar Robinson Co-Founder & Chairman
You’re viewing 4 of 7 executive team members. Get the full list »

Nextera Board Members (6)

Name Representing Role Since
Anders Tuv Self Board Member 000 0000
Bent Jakobsen Ph.D Self Board Member 000 0000
Hans Ivar Robinson Self Co-Founder & Chairman 000 0000
Martin Welschof Ph.D Self Board Member 000 0000
Nicholas Cross Self Board Member 000 0000
You’re viewing 5 of 6 board members. Get the full list »

Nextera Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Nextera Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Research Council of Norway Government 000 0000 000000 0
Radforsk Investeringsstiftelse Venture Capital Minority 000 0000 000000 0
Birk Venture Venture Capital Minority 000 0000 000000 0
To view Nextera’s complete investors history, request access »

Ready to get started?

Request a free trial